


PHARMACEUTICAL 2022



Cryoport Inc. Rank 195 of 475





PHARMACEUTICAL 2022



Cryoport Inc. Rank 195 of 475

The relative strengths and weaknesses of Cryoport Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cryoport Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 159% points. The greatest weakness of Cryoport Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is -54%, being 223% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	693,516
Cost of Goods Sold	126,031
Intangible Assets	348,381
Liabilities, Current	42,645
Liabilities, Non-Current	18,442
Other Assets	22,044
Other Compr. Net Income	-6,619
Other Expenses	1,686
Other Liabilities	410,055
Other Net Income	-256,013
Property and Equipment	49,029
Research and Development	16,843
Revenues	222,608
Selling, General and Administrative Expense	97,563

Output Variable	Value in 1000 USD
Assets	1,112,970
Liabilities	471,142
Expenses	242,123
Stockholders Equity	641,828
Net Income	-275,528
Comprehensive Net Income	-278,838
Economic Capital Ratio	-54%

